Difference between revisions of "Chromogranin"
m |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
|- | |- | ||
| Source | | Source | ||
| − | | | + | | Bos taurus |
|- | |- | ||
| Subcellular localization | | Subcellular localization | ||
| − | | | + | | Secreted |
|- | |- | ||
| Swissprot ID | | Swissprot ID | ||
| Line 35: | Line 35: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | |- | + | | |
| + | |- | ||
| Disorder prediction | | Disorder prediction | ||
| [http://iupred.enzim.hu/index.html IUPred] | | [http://iupred.enzim.hu/index.html IUPred] | ||
Latest revision as of 06:15, 2 September 2007
| Template:Infobox header| Chromogranin | |
|---|---|
| Chromogranin | |
| Substrate peptide name | Chromogranin |
| Synonyms | - |
| Determination type | In vitro |
| Source | Bos taurus |
| Subcellular localization | Secreted |
| Swissprot ID | P05059 |
| Reactive glutamines | Not determined yet |
| Reactive lysines | Not determined yet |
| Substrate sequence | |
| Structure | 1N2Y |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:5132120 |
| Notes | |
| Template:Infobox header | | |
